pasireotide 20 MG Injection

Known as: PASIREOTIDE 20MG/KIT INJ,SUSP,SA, PASIREOTIDE 20MG/KIT SA INJ SUSP, pasireotide (as pasireotide pamoate) 20 MG Injection 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
01220112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background A phase II trial of pasireotide was performed to assess its efficacy and safety in advanced or metastatic… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2018
2018
PURPOSE Medullary thyroid cancer (MTC) is a neuroendocrine tumour of the thyroid C cells. Pasireotide, a multi-receptor targeted… (More)
Is this relevant?
2017
2017
BACKGROUND Long-term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a novel… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
2017
2017
Background Several studies have demonstrated the antitumor activity of first-generation somatostatin analogs (SSAs), primarily… (More)
  • table 1
  • table 2
Is this relevant?
2016
2016
BACKGROUND Acromegaly is a rare disorder characterized by the over-production of growth hormone (GH). Patients often experience a… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2015
2015
Pasireotide LAR (SOM230 LAR) is a cyclohexapeptide engineered to bind to multiple somatostatin receptor subtypes to mimic the… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
2015
2015
Purpose: Few treatment options are available for patients with advanced or metastatic hepatocellular carcinoma (HCC). Based on… (More)
  • table 2
  • figure 2
  • figure 1
Is this relevant?
2013
2013
Pasireotide (SOM230), a novel multireceptor ligand somatostatin analog (SSA), binds with high affinity to four of the five… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2012
2012
Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2011
2011
2040 Background: Patients with recurrent or progressive meningiomas who have exhausted surgical and radiation options have… (More)
Is this relevant?